Investigating how imaging and blood tests can predict responses to lung cancer treatments
Official title: Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays
Funded at University of Washington · NIH-10992106 · Data updated 2026-11-12
This study is looking at how well patients with advanced lung cancer respond to a mix of chemotherapy and immunotherapy by using special imaging and blood tests, with the goal of personalizing treatments to help improve survival and reduce side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | December 20, 2021 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $608,411 |
| NIH project number | 5R01CA258997-04 |
| Project ID | NIH-10992106 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with newly diagnosed metastatic non-small cell lung cancer who are starting standard chemotherapy and immunotherapy treatments.
✕Less likely to help
Patients with early-stage lung cancer or those who have not been diagnosed with metastatic disease may not benefit from this research.
What this research studies
This research focuses on improving treatment outcomes for patients with metastatic non-small cell lung cancer (NSCLC) by using advanced imaging techniques and blood tests to identify how well patients respond to combined therapies of chemotherapy and immunotherapy. The study aims to assess treatment responses through positron emission tomography (PET) imaging and the analysis of circulating biomarkers in the blood. By understanding these responses, the research seeks to tailor treatments more effectively, potentially leading to better survival rates and reduced side effects for patients. The approach emphasizes precision medicine, aiming to select the right treatment for the right patient at the right time.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for lung cancer patients, improving survival rates and minimizing unnecessary side effects.
How similar studies have gone: Previous research has shown promising results in using imaging and biomarkers to guide treatment decisions in cancer therapy, indicating that this approach has potential for success.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Bowen, Stephen R. — University of Washington
- Study coordinator: Bowen, Stephen R.
Related research
Other NIH-funded projects on the same topics.
-
PET/CT scans and blood tests to guide immunotherapy, chemotherapy, and focused radiation for metastatic lung cancer
This project combines PET/CT imaging and blood immune tests to help identify which people with metastatic non‑small cell lung cancer will benefit from immunotherapy plus chemotherapy and targeted radiation.
-
Safer lung cancer radiotherapy with smart AI helpers
A new AI-based method aims to precisely map tumors and nearby organs during lung cancer radiotherapy to reduce side effects and improve outcomes.
-
Stopping chemotherapy from weakening immunotherapy in non-small cell lung cancer
This project looks at whether common chemotherapy makes lung tumors release substances that turn off immune cells and whether blocking that process could help immunotherapy work better for people with non-small cell lung cancer.
-
Improving PET/CT imaging for lung cancer immunotherapy
This project builds better PET/CT imaging methods and a shared online resource to help immunotherapy for people with non-small cell lung cancer.
-
Improving lung cancer radiation treatment with AI
This work aims to make radiation treatment for lung cancer safer and more effective by using new artificial intelligence tools.
-
Using AI to improve radiation therapy for lung cancer
This study is looking at how to use artificial intelligence to make better images for radiation therapy in patients with early-stage non-small cell lung cancer, so that doctors can more accurately target the treatment as the tumor changes, which could lead to better results for you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.